You can buy or sell MNLO and other stocks, options, ETFs, and crypto commission-free!
Menlo Therapeutics Inc. operates as biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Markets InsiderMar 20
Menlo Therapeutics Announces New Board Member Elisabeth Sandoval
REDWOOD CITY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board of Directors, effective immediately. Ms. Sandoval currently serves as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, previously served as Chief Comme...
Stock Price, News, & Analysis for Menlo Therapeutics
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known ...
Associated PressFeb 27
Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
REDWOOD CITY, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the fourth quarter and year ended December 31, 2018 and provided an update on its clinical development programs. “We are making solid progress in the clinical development of serlopitant for pruritus associated with prurigo nodularis (PN), our most advanced i...
Expected May 8, After Hours